KOD - Kodiak Sciences Inc

KOD - Kodiak Sciences Inc

https://kodiak.com

Sell Momentum: Bearish

Recent News

Powered by Alpha Vantage

Why Is Kodiak Sciences ( KOD ) Down 1.2% Since Last Earnings Report?

Zacks Commentary • 3 days ago • score: 0.13

Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Cramer: Kodiak Sciences Is A 'Pure Spec' Stock, 'No Go From Me' - Carrier Global ( NYSE:CARR ) , Kodiak Sciences ( NASDAQ:KOD )

Benzinga • 2 weeks, 5 days ago • score: 0.26

Kodiak Sciences is a "pure spec" stock, says Cramer. See the seasonal trading strategy that's beating the S&P 500 by 6X this year. Details here → On the latest edition of CNBC's "Mad Money Lightning Round," Jim Cramer called Kodiak Sciences Inc. KOD is a "pure spec" stock.

Why Is Kodiak Sciences ( KOD ) Up 10.5% Since Last Earnings Report?

Zacks Commentary • 3 months ago • score: 0.23

Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Down -28.08% in 4 Weeks, Here's Why You Should You Buy the Dip in Kodiak Sciences ( KOD )

Zacks Commentary • 5 months, 2 weeks ago • score: 0.16

Kodiak Sciences (KOD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Kodiak Q4 Loss Narrower Than Expected, Pipeline Development in Focus

Zacks Commentary • 5 months, 2 weeks ago • score: -0.02

KOD reports a narrower-than-expected loss for the fourth quarter of 2024. The company provides updates regarding its pipeline development plans.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

Kodiak Sciences Inc., a clinical-stage biopharmaceutical company, is dedicated to researching, developing, and marketing therapies to treat retinal diseases in the United States and international markets. The company is headquartered in Palo Alto, California.

52W High

$11.60

52W Low

$1.92

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

2.45

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-0.12

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

7.91

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

5.52%

Institutions (25–75% balanced)

79.24%

Shares Outstanding

52,822,000

Float

29,509,400

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

0

EPS (TTM)

-3.79

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-1.40%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

0.5044

Previous

0.5860

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025